Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman Sells 60,984 Shares

Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman sold 60,984 shares of Cerus stock in a transaction on Friday, March 7th. The shares were sold at an average price of $1.50, for a total value of $91,476.00. Following the completion of the sale, the chief executive officer now directly owns 4,309,758 shares of the company’s stock, valued at $6,464,637. This trade represents a 1.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

William Mariner Greenman also recently made the following trade(s):

• On Tuesday, March 4th, William Mariner Greenman sold 23,023 shares of Cerus stock. The shares were sold at an average price of $1.55, for a total value of $35,685.65.

Cerus Stock Down 2.6 %

Shares of Cerus stock opened at $1.47 on Tuesday. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. Cerus Co. has a 12 month low of $1.38 and a 12 month high of $2.54. The business has a fifty day simple moving average of $1.74 and a 200 day simple moving average of $1.79. The stock has a market cap of $273.11 million, a PE ratio of -13.36 and a beta of 1.56.

Cerus (NASDAQ:CERS) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01). Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. The business had revenue of $50.81 million during the quarter, compared to analysts’ expectations of $50.81 million. Research analysts predict that Cerus Co. will post -0.08 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.00 price objective on shares of Cerus in a research note on Friday, February 21st.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CERS. ARK Investment Management LLC lifted its holdings in Cerus by 14.2% during the fourth quarter. ARK Investment Management LLC now owns 20,814,752 shares of the biotechnology company’s stock worth $32,055,000 after acquiring an additional 2,589,721 shares in the last quarter. Wasatch Advisors LP lifted its holdings in Cerus by 13.6% during the fourth quarter. Wasatch Advisors LP now owns 8,319,841 shares of the biotechnology company’s stock worth $12,813,000 after acquiring an additional 994,007 shares in the last quarter. Millennium Management LLC lifted its holdings in Cerus by 52.1% during the fourth quarter. Millennium Management LLC now owns 2,877,932 shares of the biotechnology company’s stock worth $4,432,000 after acquiring an additional 986,286 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in Cerus by 2,084.7% during the fourth quarter. Squarepoint Ops LLC now owns 492,732 shares of the biotechnology company’s stock worth $759,000 after acquiring an additional 470,178 shares in the last quarter. Finally, Senvest Management LLC lifted its holdings in Cerus by 6.5% during the fourth quarter. Senvest Management LLC now owns 6,393,979 shares of the biotechnology company’s stock worth $9,847,000 after acquiring an additional 387,603 shares in the last quarter. 78.37% of the stock is currently owned by institutional investors.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.